Pfizer stock (US7170811035): Q1 earnings beat estimates with $14.5B revenue

Pfizer released its first-quarter 2026 earnings on May 5, 2026, posting revenue of $14.45 billion, a 5.4% year-over-year increase that surpassed analyst estimates of $13.84 billion, according to TipRanks as of May 2026. Earnings per share reached $1.31 on a trailing basis, with quarterly EPS at $0.47, just above the $0.43 quarterly dividend. The results highlight resilience in key products despite patent expirations.

As of: 13.05.2026

By the editorial team – specialized in equity coverage.

Pfizer: core business model

Pfizer develops and markets innovative medicines and vaccines worldwide, focusing on areas like oncology, immunology, rare diseases, and internal medicine. The company operates through a biopharma model, investing heavily in R&D to bring novel therapies to market. With a portfolio spanning branded drugs and vaccines, Pfizer generates revenue primarily from sales to healthcare providers, pharmacies, and governments. Its US listing on NYSE under ticker PFE provides key exposure for American investors tracking healthcare giants.

The business emphasizes blockbuster products and strategic acquisitions, such as the Seagen deal to bolster oncology. Pfizer's scale enables global distribution, with manufacturing sites across multiple continents supporting supply to the US market, which remains a top revenue contributor.

Main revenue and product drivers for Pfizer

Oncology drugs like Ibrance and Padcev, alongside vaccines such as Prevnar, drive a significant portion of sales. Q1 2026 revenue growth reflected strength in these segments, per the MarketBeat earnings summary as of May 2026. Internal medicine products like Eliquis also contribute steadily, with overall revenue up 5.4% year-over-year to $14.45 billion for the quarter ended March 2026.

Comorbidities revenue from cardiovascular and diabetes treatments adds diversification. Pfizer's pipeline includes potential catalysts in gene therapy and obesity, positioning it for future growth amid US healthcare spending trends.

Industry trends and competitive position

The pharmaceutical sector faces patent cliffs but benefits from rising demand for biologics and precision medicine. Pfizer competes with peers like Eli Lilly and Merck, holding a strong position via its vaccine leadership and oncology expansion. US investors note Pfizer's role in national health initiatives, including COVID-era vaccines that built lasting infrastructure.

Why Pfizer matters for US investors

As a NYSE-listed blue-chip with deep US roots in New York, Pfizer offers dividend stability and exposure to America's $4 trillion healthcare market. Its products serve Medicare and commercial payers, tying performance to US economic health and policy shifts like drug pricing reforms.

Conclusion

Pfizer's Q1 2026 earnings demonstrated operational strength with revenue beats and EPS coverage for its dividend, even as patent pressures loom. The company continues advancing its pipeline while leveraging established franchises. Investors monitor upcoming catalysts like new approvals amid a dynamic pharma landscape.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.